Posted On: 10/25/2015 9:02:26 PM
Post# of 1460
It wouldn't be surprising to see another dip designed to take out people who bought well on Friday.
Every biotech is risky, but given the gigantic unmet need for an Alzheimer's drug that works even a little bit, and the fact that AVXLD's drug is NOT going down the same old failed pathways -- and, the fact that they are uplisting AND presenting test results in the next 2 weeks -- I think that those who hang on will be rewarded.
Talking my book.
Every biotech is risky, but given the gigantic unmet need for an Alzheimer's drug that works even a little bit, and the fact that AVXLD's drug is NOT going down the same old failed pathways -- and, the fact that they are uplisting AND presenting test results in the next 2 weeks -- I think that those who hang on will be rewarded.
Talking my book.
(0)
(0)
